Search for: "Mylan Pharmaceuticals"
Results 521 - 540
of 739
Sorted by Relevance
|
Sort by Date
31 Aug 2022, 11:12 am
According to the announcement, the drug product titled “Copaxone”, manufactured by Teva Pharmaceuticals is compatible with Autoject 2. [read post]
25 Jul 2018, 10:30 am
Mylan Pharmaceuticals Inc. [read post]
30 Nov 2021, 9:36 am
Mylan Pharma Inc. [read post]
7 Sep 2010, 6:10 pm
biuras, Amgen Europe BV (The SPC Blog) Aricept (Donepezil) – US: District Court denies Apotex declaratory judgment motion on generic Aricept; does not accept ‘prompt launch’ and ‘indefinite delay’ jurisdiction theories (FDA Law Blog) Chantix (Varenicline) – US: Pfizer files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (AboutLawsuits.com) Copaxone (Glatiramer) – US: Court denies Sandoz/Momenta’s summary… [read post]
22 Mar 2011, 4:21 pm
General New IP resource for Pharma, Biotech and Chem – Compulsory licences, comparing national requirements (IP Think Tank) WIPO and India partner to protect traditional knowledge from misappropriation (WIPO) UN Rapporteur for the Right to Health asked to intervene in the TPP negotiation (KEI) Patents and doctors, and the USTR TPP text (KEI) Biotech industry losing interest in the therapeutic potential of RNAi (Patent Docs) India: The curious case of the ‘data exclusivity’ volte… [read post]
31 Oct 2008, 11:53 am
You can separately subscribe to the Pharma & Biotech edition of the IP Think Tank Global Week in Review by subscribing by email, or selecting ‘all posts’ or ‘Pharma, Biotech & Chem’ for the RSS option at the Subscribe page: [duncanbucknell.com] Highlights this week included: Oxytrol (Oxybutynin) - US: Watson files patent infringement lawsuit against Barr over application to market generic Oxytrol; Barr challenges Oxytrol patent… [read post]
8 Dec 2010, 2:20 am
(America-Israel Patent Law) Ziagen (Abacavir) – US: Mylan’s Matrix receives tentative FDA approval under PEPFAR for Abacavir Sulfate tablets, 60 mg (SmartBrief) [read post]
6 Oct 2010, 4:22 am
(profitability through simplicity) US: Yeda Appeals Board decision favoring Abbott in TBP-II interference (Holman’s Biotech IP Blog) US: Jury finds Scruggs wilfully infringed Monsanto patents, awards at least $9 million in damages (Holman’s Biotech IP Blog) US: Marcy Kaptur’s bill to create a compulsory license for patented seeds: the Seed Availability and Competition Act of 2009 (KEI) US: Glaxosmithkline Biologicals seeks review of BPAI decision concerning isolated protein from B… [read post]
9 Mar 2011, 3:00 am
Bayer AG (FDA Law Blog) (Patent Docs) Dexilant (Dexlansoprazole) – US: Takeda files patent infringement suit against Handa following Para IV certification filing (Patent Docs) EpiPen – US: Orange Book patent delisting counterclaim raised in 505(b)(2) application patent infringement litigation; decision could provide guidance on drug delivery system patent listability: King Pharmaceuticals v Intelliject (FDA Law Blog) Fentora (Fentanyl) – US: Cephalon files… [read post]
21 Mar 2011, 10:26 am
”[11] Another well-known case involved Perry Capital’s innovative investments in King Pharmaceuticals and Mylan Laboratories. [read post]
20 Jul 2011, 4:04 am
– Economic Times reports ‘Letter of Understanding’ between EU and India (Spicy IP) (Generic Pharmaceuticals and IP) France considers paralysing IP rights on the appearance of generic drugs (Class 46) India: Application of Orphan Drug Act to section 3(d)? [read post]
29 Jul 2013, 12:16 pm
Mylan Pharmaceuticals Inc. et al., C.A. [read post]
22 Dec 2010, 3:01 am
Mylan Inc. et al. [read post]
27 Jul 2011, 1:01 am
KG (TTABlog) US: ALJ Rogers sets 17-month target date in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog) Products Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaints against APP Pharmaceuticals in Delaware and S D Indiana in response to Para IV certification filing (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of… [read post]
6 Jul 2023, 2:55 am
One case between Biogen and Mylan is worth mentioning. [read post]
10 Jan 2012, 7:58 am
Mylan Pharmaceuticals, Inc., 2011 U.S. [read post]
25 Jun 2020, 3:49 am
A key part of the basis for arguing that damages will not be an adequate remedy in any pharmaceutical case is often the price spiral that will occur if multiple generics launch. [read post]
20 Sep 2016, 4:29 am
| Good news and bad news for bio-pharmaceutical patenting in the United States | HP? [read post]
1 Jul 2020, 1:15 am
Mylan, upholding Marcus Smith J.'s decision to deny an interim injunction against a generic company which launched at risk.Fellow GuestKat Rose Hughes reported on the judgment of the UK Supreme Court in Regeneron v Kymab, which found Regeneron's patents to be invalid for insufficiency, overturning the Court of Appeal decision and confirming the UK's strong sufficiency requirement.Trade MarksPermaKat Neil J. [read post]
14 May 2019, 11:24 am
Mylan Labs., Inc., 464 F.3d 1286,1289 (Fed. [read post]
